Abstract:Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-age women. PCOS women often have increased central adiposity, insulin resistance, and renal injury. Hyperandrogenism is prevalent in PCOS women and is positively associated with metabolic dysfunction. Androgens bind to the androgen receptor (AR) to impart downstream transcriptional activity. Targeting the AR may alleviate PCOS complications, however the use of AR blockers is limited by their severe adverse effects in females thus safer alternative approaches are highly needed. ARV-110, a novel AR Proteolysis Targeting Chimera (PROTAC) degrader demonstrates high efficacy to prevent AR signaling in prostate cancer, however its efficacy in PCOS is unknown. Using a well-established hyperandrogenemic mouse model of PCOS, we aim to test the hypothesis that decreasing AR protein levels with ARV-110 will ameliorate androgen-mediated derangements in PCOS. Methods: Three-week old female mice (C57BL/6N) were implanted with Silastic tubes filled with the androgen dihydrotestosterone (DHT, 8mg, S.C., 90 days) or vehicle (n=6/grp). Four weeks post-DHT administration, mice were treated with ARV-110 (1 mg/kg/day, S.C.) for an additional 8 weeks. Body composition (EchoMRI) and the oral glucose tolerance test (OGTT) were assessed. Retroperitoneal fat (RPF) and kidney weights were measured by gravimetry. AR and extracellular matrix (ECM) remodeling marker MMP9 protein levels were assessed by Western blot, while the pro-fibrotic marker TGF-β was assessed by ELISA. Results: DHT mice showed significant (p<0.05) increases in body weight (27.3±0.6 vs 23.9±0.26 g), fat mass (4.2±0.6 vs 2.1±0.1 g), lean mass (21.6±0.2 vs 19.8±0.2 g), as well as RPF (244.4±37.4 vs 50.0±1.8 mg) and kidney weights (491.3±7.69 vs 303.1±5.5 mg) compared to controls. DHT increased fasting glucose (183.2±25.2 vs 141.5±9.9 mg/dL, p<0.05) and impaired OGTT (AUC:34557±6255 vs 23459±1896 mg.min/dL, p<0.05). ARV-110 treatment ameliorated all aforementioned DHT-mediated changes. On the molecular level, DHT mice had higher AR expression in RPF (1.5-fold) and kidney (2.5-fold), and higher MMP9 in both tissues (2- and 1.5-fold, respectively) indicating ECM remodeling. DHT had no significant effect on TGF-β in RPF but it upregulated TGF-β level in the kidney (2-fold, p<0.05). ARV-110 successfully decreased both RPF and renal AR protein levels by 70% in DHT mice compared to vehicle-treated DHT. Excitingly, while ARV-110 did not modulate RPF nor renal TGF-β levels, it completely abolished DHT-mediated MMP9 increase in both tissues. Conclusion and significance: Our findings suggest that DHT-mediated WAT expansion, kidney hypertrophy, and associated ECM remodeling are ameliorated by ARV-110 in DHT mice. These results highlight the pivotal role of AR in androgen-mediated and tissue-specific derangements common in PCOS. AR PROTACs could be a novel therapeutic approach to treat metabolic and renal dysfunction in PCOS. Supported by National Institute of General Medical Sciences of the National Institutes of Health grant P20GM121334 (L.L.Y.C. and D.G.R.), and American Heart Association Predoctoral Fellowship 903804 (A.M.H.) This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Hepatocyte Androgen Receptor in Females Mediates Androgen-Induced Hepatocellular Glucose Mishandling and Systemic Insulin Resistance

Androgen-induced Insulin Resistance is Ameliorated by Deletion of Hepatic Androgen Receptor in Females.

Comparison of Reproductive Function Between Normal and Hyperandrogenemia Conditions in Female Mice With Deletion of Hepatic Androgen Receptor

Androgen receptor functions in pericentral hepatocytes to decrease gluconeogenesis and avoid hyperglycemia and obesity in male mice

1577-P: Hepatic Steatosis and Glucose Intolerance in Liver-Specific Estrogen Receptor Alpha Knockout Mice

Insulin And Leptin Resistance With Hyperleptinemia In Mice Lacking Androgen Receptor

SAT362 Low-dose DHT’s Effects On Gluconeogenesis And Energy Metabolism Are Ameliorated By Central Nervous System Knockout Of The Androgen Receptor

SAT002 Liver-specific Loss Of The Nuclear Receptor Co-regulator ARGLU1 Protects Against Diet-induced Obesity In Female Mice Independent Of Food Intake And Energy Expenditure

Impaired adipose expansion caused by liver X receptor activation is associated with insulin resistance in mice fed a high-fat diet.

Trace glucose and lipid metabolism in high androgen and high-fat diet induced polycystic ovary syndrome rats

Aromatase deficiency in hematopoietic cells improves glucose tolerance in male mice through skeletal muscle-specific effects

Regulation Of Insulin Resistance And Adiponectin Signaling In Adipose Tissue By Liver X Receptor Activation Highlights A Cross-Talk With Ppar Gamma

Hepatic estrogen receptor α is critical for regulation of gluconeogenesis and lipid metabolism in males

Novel Androgen Receptor PROTAC Degrader ARV-110 Ameliorates White Adipose Tissue and Kidney Structural Derangements in a Mouse Model of Polycystic Ovary Syndrome

Targeted overexpression of androgen receptor with a liver-specific promoter in transgenic mice.

Elevated androgen levels induce hyperinsulinemia through increase in Ins1 transcription in pancreatic beta cells in female rats

Hepatic Insulin Resistance in Mice with Hepatic Overexpression of Diacylglycerol Acyltransferase 2.

Androgen receptor actions on AgRP neurons are not a major cause of reproductive and metabolic impairments in peripubertally androgenized mice

Impaired Carbohydrate Metabolism and Excess of Lipid Accumulation in Offspring of Hyperandrogenic Mice

Androgen receptor coordinates muscle metabolic and contractile functions

Hepatic Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT) Regulates Metabolism in Mice